According to a filing dated 3 November 2025, Zylox-Tonbridge Medical Technology Co., Ltd. (stock code: 02190) reported that as of 31 October 2025, its total authorised share capital remained at RMB 330,182,001, comprising 322,400,744 H Shares and 7,781,257 Domestic Shares.

In terms of issued H Shares, there was a reduction of 947,000 in publicly held shares for the month, bringing the total outstanding H Shares to 315,804,613. Concurrently, treasury H Shares increased by 947,000, reaching 6,596,131 shares in total. Domestic Shares remained unchanged with 7,781,257 shares in issue and no treasury holdings.

Additionally, the company noted two existing share-related plans: a Share Award Scheme adopted on 19 December 2024 and a 2025 Share Incentive Scheme, under which a total of 13,950,000 RSUs have been granted. No new shares were issued pursuant to these plans during the reported period.